AzTrials
AzTrials

Posttraumatic Stress DisordersPhase 3NCT01743664

The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis

A Phase 3 study testing EMDR and Relaxation in people with Posttraumatic Stress Disorders and Multiple Sclerosis, run by San Luigi Gonzaga Hospital at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Multiple Sclerosis (MS) can be associated to many psychological symptoms. One of the most relevant is the experience of distress related to the disease, that can lead to the development of Post Traumatic Stress Disorder (PTSD). Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
EMDR and Relaxation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteItaly
Study dates
May 2010to Feb 2014
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • definite diagnosis of MS (Mc Donald Criteria) evaluated by a neurologist at least six months previously;
  • a relapsing-remitting, primary or secondary progressive disease;
  • clinically inactive phase of the disease;
  • fluent Italian speaker;
  • legal capacity to consent to the treatment;
  • diagnosis of PTSD assessed with the SCID;
  • willingness to suspend all concomitant psychological treatment and suspension of all psychotropic medications at least one month before the treatment or maintenance at baseline level throughout the study.

Who cannot join

  • other serious mental disorders, including bipolar disorders, psychotic symptoms, substance abuse, suicidal tendency or cognitive impairment;
  • in corticosteroid treatment during the previous month;
  • with other serious medical disorders in addition to MS.

Trial locations and contacts

1 site in 1 country.

Luca Ostacoli, M.D. contact

0039 0119026664

luca.ostacoli@unito.it

Italy1 site, 1 recruiting
  • San Luigi Gonzaga University Hospital

    Orbassano, Torino, 10043

    Luca Ostacoli, M.D.

    Recruiting

Other trials in Italy

About this study

Official title: The Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Patients With Post Traumatic Stress Disorder in Multiple Sclerosis. A Randomized Controlled Trial.

Multiple Sclerosis (MS) can be associated to many psychological symptoms. One of the most relevant is the experience of distress related to the disease, that can lead to the development of Post Traumatic Stress Disorder (PTSD). As far as we know there are no studies on the efficacy of psychological treatments in MS in spite of its relevance for patients' quality of life. Primary aim is to evaluate the efficacy of the treatment with Eyes Movement Desensitization and Reprocessing(EMDR) in PTSD secondary to MS. EMDR is the elective treatment (together with Cognitive Behavioural Therapy) for PTSD according to international guidelines. The secondary aims are to evaluate the efficacy of EMDR on the PTSD-associated symptoms of anxiety and depression and Quality of Life. The study design is a randomized clinical trial. Sixty patients with MS and PTSD will be pre-screened by using the IES-R and the Clinician Administered PTSD Scale. The patients will be randomized in two groups (30 in the experimental group and 30 in the control group).The psychological assessment will be performed in both groups with the same timing and tools: at baseline (T0), after treatment (T1) and 6 months later (T2) by two trained clinical psychologists (independent and blind to treatment) with the CAPS and the administration of self reports: Trauma Antecedent Questionnaire, Chicago Multiscale Depression Inventory, Hospital Anxiety and Depression Scale and Functional Assessment of Multiple Sclerosis. The experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events. The efficacy will be evaluated comparing the results between T0, T1 and T2 and comparing the scores of the experimental and the control groups. Primary outcome measures will be: 1) the proportion of participants at T1 and T2 no longer meeting the Diagnostic and Statistical Manual (DSM IV-TR) diagnostic criteria for PTSD; 2) the reduction of CAPS scores for the four PTSD dimensions from pre-treatment to post-treatment evaluation and follow-up (avoidance, reexperiencing the traumatic event, hyperarousal and numbing). Secondary outcome measures will be: comparison of the scores of CMDI, HADS and FAMS of the two groups at T0, T1 and T2. The statistical procedure applied will be a repeated measures analysis of covariance both on the primary outcome continuous measures and on the secondary ones.

Read the detailed description

Multiple Sclerosis (MS) is a chronic neurological disease of the Central Nervous System (CNS) that affects both the brain and the spinal cord by destroying the myelin sheath that protects the nerve fibers, leaving plaques or scars on the damaged sites. MS shows a wide range of psychological and psychological-related symptoms, including psychiatric aspects, fatigue and cognitive deficits. In particular, there is a strong evidence of psychiatric disorders associated with MS, the most common being depression, adjustment disorder and anxiety. These occur more frequently at the time of diagnosis communication, during the earlier phases of development of the disease and during relapse episodes. Some studies report a significant association between stressful life-events and relapses, in some cases pointing to frequency and number of stressors as an enhancing factor that can predict a relapsing episode.

The patients may experience distress not only in association with external stressors, but also in relation to the onset or the progression of the disease itself. Diagnosis, relapsing episodes and a worsening of physical functioning may be perceived as traumatic events and may give rise to physiological and emotional posttraumatic symptoms and, in some cases, to Post Traumatic Stress Disorder (PTSD). According to the DSM IV-TR, PTSD is a clinical condition characterised by "the development of characteristic symptoms following exposure to an extreme traumatic stressor involving direct personal experience of an event that involves actual or threatened death or serious injury or other threat to physical integrity. The person's response to the event must involve intense fear, helplessness. The characteristic symptoms resulting from the exposure to the extreme trauma include persistent re-experiencing of the traumatic event, persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness and persistent symptoms of increased arousal. The full symptom picture must be present for more than one month and the disturbance must cause clinically significant distress or impairment in social, occupational or other important areas of functioning" [DSM IV]. Many psychological treatments are available for PTSD, ranging from individual therapy to family therapy and support groups together with interpersonal, relational and psychodynamic psychotherapies; their focus is to desensitise the trauma memory and the meaning of the trauma as well as its power to affect relationships. Among these therapies, the two elective treatments according to international guidelines are the Trauma-focused Cognitive-Behavioural Therapy(CBT-TF) and Eye Movement Desensitisation and Reprocessing (EMDR). CBT-TF focuses on thoughts and beliefs helping people to overcome fear about their painful memories by talking about the trauma repeatedly or by imagining the situation that is realistically safe although still frightening. EMDR is based on the accelerated information processing model integrating elements of different psychotherapies and it is applied through an eight-phase approach. In the EMDR, the patient is induced to focus on his/her negative thoughts, image and body sensation while receiving an "alternate stimulus" (such as eye movements, hand taps or sounds). This procedure leads to desensitisation and emotional reprocessing.

The aims of the study are aim to evaluate whether a treatment based on the EMDR protocol can resolve PTSD or reduce PTS symptoms, also improving the PTS-associated symptoms, such as anxiety and depression. Primary objective : to evaluate the efficacy of the treatment with EMDR on the PTSD in MS. Secondary objectives : To evaluate whether after treatment with EMDR there is an improvement in PTS-associated symptoms of anxiety and depression and an improvement in quality of life.

The recruitment of the patients proceed with a two-step screening: 1) the Impact of Event Scale Revised (IES-R) will be administered to consecutive patients corresponding to the neurological inclusion and exclusion criteria, specifying in the instructions that they consider only the illness as the traumatic event. 2) Patients with scores above the cut off of 33 will be assessed with the SCID in order to confirm diagnosis of PTSD. The research protocol will be proposed to patients with PTSD who meet the inclusion/exclusion criteria, with an explanation of the aims of the study, its relevance for MS patients and the possibility that they may be included, by random assignment, in the treatment or control group for the period of the study, with the same timing and assessment tools. If they agree, they sign the informed consent. Patients will be randomised to the intervention (A) or control (B) group using a block-wise randomisation sequence (block size of 10). Assessment Measures: All patients are evaluated by neurologists with the Expanded Disability Status Scale (EDSS).

The psychological assessment of the patients entering the study will be performed at T0 (baseline evaluation), at T1 (post-treatment evaluation after 12 weeks) and at T2 (follow up evaluation six months later) to determine the reliability of the results.

Measures:

  • CLINICIAN ADMINISTERED PTSD SCALE (CAPS): the CAPS is a clinical semi-structured interview based on the DSM IV-TR, which is the gold standard to assess PTSD. It is a 30-item structured interview that meets the DSM IV criteria for PTSD. It assesses 4 dimensions of the PTSD: avoidance, reexperiencing the traumatic event, hyperarousal and numbing. Dissociative symptoms are measured by the three CAPS dissociation items (depersonalization, derealization, and reduction in awareness of one's surroundings). It can be used to make a current (past month) or life-time diagnosis of PTSD or to assess symptoms over the past week.
  • TRAUMA ANTECEDENT QUESTIONNAIRE (TAQ): an interview based questionnaire to assess the trauma load due to previous traumas. The TAQ asks for the frequency (never, rarely, commonly) of experiences assigned to 11 domains (ranging from positive experiences like competence and safety, to negative experiences such as neglect, physical, emotional, sexual abuse, and witnessing trauma), separately assess four developmental periods including early childhood (0-6), middle childhood, (7-12), adolescence (13 18), and adults (19+).
  • CHICAGO MULTISCALE DEPRESSION INVENTORY (CMDI): the CMDI is a 42-item, self-reporting questionnaire and was developed to assess depression in MS and other chronic diseases. It has three subscales designed to be used either separately or in combination. The mood subscale provides a more conservative indication of depression than total CMDI score and other depression tools.
  • HOSPITAL ANXIETY AND DEPRESSION SCALE (HADS): the HADS was developed to identify caseness (possible and probable) of anxiety disorders and depression among patients in non-psychiatric hospital clinics. It is divided into an Anxiety subscale (HADS-A) and a Depression subscale (HADS-D) both containing seven intermingled items . The tool has long been used in studies that involve patients with MS.
  • FAMS: Quality of life. The FAMS is a factorially derived self-report scale designed to assess six primary aspects of QOL of patients with MS: Mobility, Symptoms, Emotional Well-Being, General Contentment Thinking and Fatigue, and Family/Social Well- Being.

Treatment: The experimental group will undergo 10 sessions of 60 minutes each of treatment with the EMDR protocol. The EMDR treatment will be conducted by 3 expert psychotherapists with more than 6 years experience in the liaison setting, in possession of II level training degree in EMDR. Relaxation techniques (RT) will be performed by three psychotherapists working in the same facility. Treatments will be independent and blinded from the clinical psychologists conducting the clinical assessments.

The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy. Relaxation sessions will follow the same structure as the EMDR sessions, including diaphragmatic breathing, progressive muscle relaxation, visualisation, cue-controlled relaxation, and rapid relaxation.

The efficacy of the EMDR treatment will be evaluated by comparing the results of the tools (CAPS, CMDI, HADS, FAMS) administered to the treated group at T0, T1 and T2 and by comparing the scores of the experimental group with those of the control group. Primary outcome measures will include 1) Proportion of participants at T1 and T2 no longer meeting the DSM IV-TR diagnostic criteria for PTSD (SCID) among patients of the experimental group in comparison with those of the control group; 2) the reduction of CAPS scores for the four PTSD dimensions from pre-treatment to follow-up in both groups (avoidance, re-experiencing the traumatic event, hyperarousal and numbing).

  1. Reduction in the IES scores. Scores for anxiety, depression and quality of life will be included as secondary outcome. Dissociative symptoms will be evaluated through the three CAPS dissociation items (Taylor et al., 2003).

Additional expected results: the large number of patients assessed for post traumatic symptoms might improve knowledge both of their prevalence and also of the trauma underlying MS. Even if it is not the primary aim of the study, assessment of the trauma load through the interview-based TAQ will lead to life-trauma evaluation which may be studied for their correlation with the onset of the disease and its emotional correlates. Moreover, in EMDR, associated traumas are defined and treated: given that sessions are video-recorded, their analysis (beyond the three sessions that will be reviewed for treatment fidelity) may add knowledge to the role of the trauma load in MS.

Being tested
EMDR, Relaxation
Keywords
Posttraumatic Stress Disorders, Multiple Sclerosis, Eye Movement Desensitization Reprocessing, Psychotherapy, Anxiety, Depression, Quality of Life
Medical subject headings
Stress Disorders, Post-Traumatic, Multiple Sclerosis, Anxiety Disorders, Depression

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EMDRBehavioural

    Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events

  • RelaxationBehavioural

    The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.

Study groups in NCT01743664
Study groupRoleWhat they receive
Eye Movement Desesitization ReprocessingExperimentalThe EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
Receives: Behavioral: EMDR
relaxationActive comparatorRelaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
Receives: Behavioral: Relaxation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of participants no longer meeting the DSM IV-TR diagnostic criteria for PTSD among patients of the experimental group in comparison with those of the control group after the treatment.

    Measured: Change from Baseline of number of patients meeting the PTSD DSM IV-TR criteria at 3 months

Secondary outcomes (3)
  1. Reduction in the IES scores after the treatment.

    Measured: Reduction from Baseline of IES-R score at 3 months

  2. Proportion of participants no longer meeting the DSM IV-TR diagnostic criteria for PTSD among patients of the experimental group in comparison with those of the control group at the follow up.

    Measured: Change from Baseline of number of patients meeting the PTSD DSM IV-TR criteria at 9 months

  3. Reduction in the IES scores at the follow-up.

    Measured: Reduction from Baseline of IES-R score at 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2012 (estimated)
  2. Study startMay 2010
  3. Primary completionMar 2013 (estimated)
  4. Study completionFeb 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01743664
Sponsor's protocol ID
2009/R/11
Status last verified
Dec 2012
First submitted
21 Nov 2012
Last updated
7 Dec 2012
Results posted
No
Data monitoring committee
No

Publications

  • Chalfant AM, Bryant RA, Fulcher G. Posttraumatic stress disorder following diagnosis of multiple sclerosis. J Trauma Stress. 2004 Oct;17(5):423-8. doi: 10.1023/B:JOTS.0000048955.65891.4c.

    PubMed 15633921
  • Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S. Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry. 2007 Feb;190:97-104. doi: 10.1192/bjp.bp.106.021402.

    PubMed 17267924
  • Kangas M, Henry JL, Bryant RA. Posttraumatic stress disorder following cancer. A conceptual and empirical review. Clin Psychol Rev. 2002 May;22(4):499-524. doi: 10.1016/s0272-7358(01)00118-0.

    PubMed 12094509
  • Tedstone JE, Tarrier N. Posttraumatic stress disorder following medical illness and treatment. Clin Psychol Rev. 2003 May;23(3):409-48. doi: 10.1016/s0272-7358(03)00031-x.

    PubMed 12729679
  • Ostacoli L, Carletto S, Borghi M, Cavallo M, Rocci E, Zuffranieri M, Malucchi S, Bertolotto A, Zennaro A, Furlan PM, Picci RL. Prevalence and significant determinants of post-traumatic stress disorder in a large sample of patients with multiple sclerosis. J Clin Psychol Med Settings. 2013 Jun;20(2):240-6. doi: 10.1007/s10880-012-9323-2.

    PubMed 23053829
  • Carletto S, Borghi M, Bertino G, Oliva F, Cavallo M, Hofmann A, Zennaro A, Malucchi S, Ostacoli L. Treating Post-traumatic Stress Disorder in Patients with Multiple Sclerosis: A Randomized Controlled Trial Comparing the Efficacy of Eye Movement Desensitization and Reprocessing and Relaxation Therapy. Front Psychol. 2016 Apr 21;7:526. doi: 10.3389/fpsyg.2016.00526. eCollection 2016.

    PubMed 27148134

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing EMDR and Relaxation in people with Posttraumatic Stress Disorders and Multiple Sclerosis, run by San Luigi Gonzaga Hospital at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Dec 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Luca Ostacoli, M.D. (0039 0119026664, luca.ostacoli@unito.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of participants no longer meeting the DSM IV-TR diagnostic criteria for PTSD among patients of the experimental group in comparison with those of the control group after the treatment. (time frame: Change from Baseline of number of patients meeting the PTSD DSM IV-TR criteria at 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01743664, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Dec 2012.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in